| Message: | Name:Tesamorelin
Sequence:H-HIS-ALA-GLU-GLY-THR-PHE-THR-SER-ASP-VAL-SER-SER-TYR-LEU-GLU-GLY-GLN-ALA-ALA-LYS-GLU-PHE-ILE-ALA-TRP-LEU-VAL-LYS-GLY-ARG-GLY-OH
CAS No.: 106612-94-6
Molecular Formula: C151H228N40O47
Molecular Weight: 3355.67
Appearance: White powder
Purity (HPLC): 98.0%
Single Impurity (HPLC): 0.5%max
Amino Acid Composition: ±10% of theoretical
Peptide Content(N%): ≥80.0%
Water Content(Karl Fischer): ≤8.0%
Acetate Content(HPIC): ≤10.0%
Specific Rotation (20/D): -55.0~-65.0°(c=1 1%HAc)
MS(ESI): Consistent
Mass Balance: 95.0~105.0%
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism. Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).
Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group. |
my account
